key: cord-0772156-e5qwzrvg authors: Petzer, Verena; Schwendinger, Simon; Haschka, David; Vogi, Verena; Tymoszuk, Piotr; Burkert, Francesco; Sahanic, Sabina; Sonnweber, Thomas; Bellmann‐Weiler, Rosa; Loeffler‐Ragg, Judith; Tancevski, Ivan; Zschocke, Johannes; Weiss, Guenter; Wolf, Dominik; Jukic, Emina title: Clonal hematopoiesis in patients with Covid‐19 is stable and not linked to an aggravated clinical course date: 2021-06-02 journal: Am J Hematol DOI: 10.1002/ajh.26251 sha: 79098740c343bea361c90a6509c69ba0419d57be doc_id: 772156 cord_uid: e5qwzrvg nan To the Editor: The strength of host immune reaction to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) determines the severity of corona virus disease 2019 . While a basic antiviral immune response involving innate immune mechanisms and an induction of adaptive immunity is needed to resolve the disease, particularly innate myeloid cells can also induce a dysregulated, excessive, aberrant and non-effective host immune response in severe Covid-19. 1 The latter is termed "hyperinflammation," "cytokine storm," "macrophage activation syndrome" or "cytokine release syndrome." Hyperinflammation contributes to the pathogenesis of Covid-19 related acute respiratory distress syndrome (ARDS), which is associated with a fatal outcome in the majority of patients, but may also induce multi-organ damage, which is the second most common cause of death in Covid-19. Thus, a better understanding of underlying host-intrinsic factors driving immune dysfunction is warranted for the immediate identification of patients at risk and eventually also for selecting novel targeted therapies. Thus, SARS-CoV-2 has been found to infect multiple cells expression ACE-2 receptors including human monocytes, macrophages and dendritic cells, emphasizing their contribution to disease pathology. 2 Of relevance, clonal hematopoiesis (CH; defined as somatic variants in the peripheral blood at a variant allele frequency ≥2%) is considered to imprint inflammation in myeloid cells, which may perpetuate acute (e.g., infectious-triggered) and chronic inflammatory processes. 3, 4 Moreover, CH is associated with some of the comorbidities relevant for higher risk of severe Covid-19, especially age and cardiovascular disease. Augmented injury in cardiovascular tissues was attributed to increased inflammatory tension in clonal myeloid and T cells, which drive pro-inflammatory circuits via NLRP3-inflammasome activation and subsequent IL-1β production. 5 Moreover, while published data regarding the risk of patients with hematological malignancies to acquire Covid-19 are discordant, these papers consistently show that these patients have a higher case fatality rate. 6 In addition, case reports of acute leukemia and concomitant Covid-19 are increasingly reported. Especially newly diagnosed, refractory or relapsed cases pose a challenge, as these patients often need immediate therapy. However, diagnostic work-up prior to therapy initiation is essential for the selection of the optimal patienttailored therapy. For example, for acute myeloid leukemia, besides a Against this background, we herein investigated the prevalence and clinical impact of CH in Covid-19. Moreover, we analyzed clonal size during the disease and upon its resolution. In total, 169 patients were screened for participation in this study. Nine patients turned out to be SARS-CoV-2 PCR negative, and thus were excluded from further analysis. Of the remaining 160 patients, 43 patients were included during hospitalization due to Covid-19 (median time to blood test for CH analysis: 24 days; range: 0-57 days), 117 patients, who were either treated as outpatients or also being hospitalized during the acute phase, were included when they came for follow-up evaluation performed between 31-119 days Statistical analysis was performed using GraphPad Prism software. In order to assess correlation between disease groups and CH, chi-square test was used. For comparison between disease groups, two-sided Mann-Whitney U test was used, because of non-normal variable distributions as assessed by Shapiro-Wilk test. p values <0.05 were considered significant. The median age of the study cohort is 57 years with 62% male individuals. Further relevant baseline characteristics of our study cohort are shown in Table S1 . To characterize the interplay between CH, inflammation and Covid-19 course, we divided our patient cohort into "severe Covid-19" and "non-severe Covide-19" based on the following criteria: Patients, requiring ≥2 L/min of supplemental oxygen support at any given time point were classified as "severe Covid-19." As shown in Figure S2 , the severity of Covid-19 is related to hyperinflammation, as "non-severe Covid-19" patients had lower CRP and IL-6 levels than "severe Covid-19" patients. Note, CH was present in 31 patients (19.4%), with a total of 46 variants affecting 11 genes (Figure 1(A) ). Variants affecting DNMT3A and TET2 were the most abundant followed by various other mutated genes at much lower frequencies ( Figure S3 ). Nine patients (29%) had more than one variant ( Figure S2C ). Compared to studies utilizing genome-wide or exome-wide sequencing approaches the prevalence of CH is higher in our study cohort. 4 As previously discussed by Buscarlet et al., this is probably due to the higher sensitivity of targeted resequencing. 7 However, the age and gene distribution of CH in our study cohort resembles the previously published frequencies very well. Higher percentages of patients with CH were found among higher age groups, except for those aged 80 years and higher, consisting only of only six patients, thus making interpretations limited ( Figure 1(B) ). Of the study cohort, 99 patients (61.9%) had non-severe Covid-19 while 61 (38.1%) had severe Covid-19 according to our criteria. Of the latter, 37 patients (23.1%) had to be admitted to an intensive care unit due to respiratory insufficiency (Table S1 ). However, the presence of CH was not associated with severe Covid-19 (Figure 1(C) ; p value: 0.678), which complements previously published data. 8 In fact, median VAF was even significantly higher in the "non-severe COVID-19" group (median: 5.5% vs. 2.7%; Figure 1(D) ). Thus, in contrast to previous studies linking higher VAFs (especially ≥10%) to a higher risk of hematological as well as cardiovascular disease risk, which was mainly explained by CH-mediated inflammatory imprinting in circulating leukocytes, CH appears to be irrelevant for the severity of Covid-19. 3 In addition, we could not define a certain pattern of variants associated with Covid-19 in general or with severe Covid-19 ( Figure 1(E) ). The representative character of our patient cohort is supported by the known association of both, male gender and we only analyzed CH positivity in these subgroups, no link to disease severity was detected (Table S1) . Of interest, therapy with a human monoclonal antibody targeting IL-1β (canakinumab) in Covid-19 has been reported to cause a reduction in inflammation, and an improved respiratory function with reduced oxygen need, implicating a potential role of IL-1β in severe Covid-19. 9 However, a randomized trial utilizing another IL-1β neutralizing drug (Anakinra) did not show any benefit. 10 Thus, the pathogenic role of IL-1β for severe Covid-19 as well as therapeutic neutralization as potential treatment needs to be further determined. Though the NLRP-3 inflammasome has been linked to CH and vascular risk, we here claim that CH is not a driving force of hyperinflammation, in particular not of NLRP-3/IL-1β induction. Accordingly, a broad inflammatory range with multiple signals has been characterized in patients suffering from severe Covid-19, where IL-1β was not among the biomarkers found to be associated with mortality. 11 Next, we analyzed the dynamics of VAF of 15 variants in eight individuals (Figure 1(F) ). Nine of these variants (60%) could be reproduced in all analyzed samples. Four additional variants (27%) could be reproduced in all samples after manual inspection. In these cases, the variants were filtered during data analysis pipeline because of low VAF or coverage. Only two variants (13%) could not be reproduced. As shown in Figure S4 , blood counts changed over time according to disease status, which had no obvious influence on the VAF of the detected aberrations. In summary, although the study has a limited sample size, we demonstrate that CH is neither over-represented in Covid-19, nor does it influence disease severity, even though CH has been linked to an inflammatory imprinting phenotype in leukocytes. Moreover, Covid-19 does not modulate the clonal composition in affected individuals, as in patients with CH the VAF is stable during the course of the disease and its resolution. Complex immune dysregulation in COVID-19 patients with severe respiratory failure Monocytes and macrophages, targets of SARS-CoV-2: the clue for Covid-19 immunoparalysis Age-related clonal hematopoiesis associated with adverse outcomes Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice COVID-19 in persons with haematological cancers DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions Clinico-biological features and clonal hematopoiesis in patients with severe COVID-19. Cancers (Basel) Efficacy of canakinumab in mild or severe COVID-19 pneumonia Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-tomoderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial An immune-based biomarker signature is associated with mortality in COVID-19 patients All authors read and corrected the manuscript. Informed consent was obtained from each patient. The data that support the findings of this study are available from the corresponding author upon reasonable request. https://orcid.org/0000-0002-9205-1440Simon Schwendinger https://orcid.org/0000-0002-7542-222X Additional supporting information may be found online in the Supporting Information section at the end of this article.